Effective gene therapy for haemophilic mice with pathogenic factor IX antibodies.
about
Role of the vector genome and underlying factor IX mutation in immune responses to AAV gene therapy for hemophilia BClinical development of gene therapy: results and lessons from recent successesTargeted approaches to induce immune tolerance for Pompe disease therapyGene therapy for hemophiliaGene therapy in an era of emerging treatment options for hemophilia BEvaluation of engineered AAV capsids for hepatic factor IX gene transfer in murine and canine modelsImmune responses and hypercoagulation in ERT for Pompe disease are mutation and rhGAA dose dependent.Immune tolerance induction to factor IX through B cell gene transfer: TLR9 signaling delineates between tolerogenic and immunogenic B cells.Cell-Mediated Immunity to AAV Vectors, Evolving Concepts and Potential Solutions.Suppression of inhibitor formation against FVIII in a murine model of hemophilia A by oral delivery of antigens bioencapsulated in plant cellsEx Vivo Expanded Autologous Polyclonal Regulatory T Cells Suppress Inhibitor Formation in Hemophilia.Development of Gene Transfer for Induction of Antigen-specific Tolerance.Immune responses to human factor IX in haemophilia B mice of different genetic backgrounds are distinct and modified by TLR4.Prevalence of anti-adeno-associated virus serotype 8 neutralizing antibodies and arylsulfatase B cross-reactive immunologic material in mucopolysaccharidosis VI patient candidates for a gene therapy trial.Plant-based oral tolerance to hemophilia therapy employs a complex immune regulatory response including LAP+CD4+ T cellsUnique Roles of TLR9- and MyD88-Dependent and -Independent Pathways in Adaptive Immune Responses to AAV-Mediated Gene TransferLow cost industrial production of coagulation factor IX bioencapsulated in lettuce cells for oral tolerance induction in hemophilia B.Copackaged AAV9 Vectors Promote Simultaneous Immune Tolerance and Phenotypic Correction of Pompe Disease.Effects of FVIII immunity on hepatocyte and hematopoietic stem cell-directed gene therapy of murine hemophilia A.Microglia-specific targeting by novel capsid-modified AAV6 vectors.Induction of Hematopoietic Microchimerism by Gene-Modified BMT Elicits Antigen-Specific B and T Cell Unresponsiveness toward Gene Therapy ProductsLow-dose Gene Therapy Reduces the Frequency of Enzyme Replacement Therapy in a Mouse Model of Lysosomal Storage Disease.Glucocorticoid-Induced TNF Receptor Family-Related Protein Ligand is Requisite for Optimal Functioning of Regulatory CD4(+) T Cells.Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodiesLow-Dose Liver-Targeted Gene Therapy for Pompe Disease Enhances Therapeutic Efficacy of ERT via Immune Tolerance Induction.The role of Rixubis™ in the treatment of hemophilia B.The Skeletal Muscle Environment and Its Role in Immunity and Tolerance to AAV Vector-Mediated Gene Transfer.New approaches to gene and cell therapy for hemophilia.In vivo induction of regulatory T cells for immune tolerance in hemophilia.Gene therapy for immune tolerance induction in hemophilia with inhibitors.Innovating immune tolerance induction for haemophilia.Liver gene therapy by lentiviral vectors reverses anti-factor IX pre-existing immunity in haemophilic miceComplexity of immune responses to AAV transgene products - Example of factor IX.Regulatory T cells and TLR9 activation shape antibody formation to a secreted transgene product in AAV muscle gene transfer.Unraveling the complex story of immune responses to AAV vectors trial after trial.Immune Modulatory Cell Therapy for Hemophilia B Based on CD20-Targeted Lentiviral Gene Transfer to Primary B Cells.The Balance between CD8+ T Cell-Mediated Clearance of AAV-Encoded Antigen in the Liver and Tolerance Is Dependent on the Vector Dose.Dynamics of antigen presentation to transgene product-specific CD4+ T cells and of Treg induction upon hepatic AAV gene transfer.Gene Therapy-Induced Antigen-Specific Tregs Inhibit Neuro-inflammation and Reverse Disease in a Mouse Model of Multiple Sclerosis.Oral Tolerance Induction in Hemophilia B Dogs Fed with Transplastomic Lettuce.
P2860
Q21245486-A353C917-4CE9-4CAC-ACC0-99CA213D503AQ26743393-5BF2C8DA-0E51-4730-AD58-C4642934F0F1Q26767363-F41E8E02-4536-4C54-B628-A3F169A8C7FBQ28081911-1BACED53-57BC-445E-B284-05AEBA3AA470Q28087557-6A2CEF23-5C1D-47D8-BC13-FA05B011A34CQ33623549-FD886D6F-A534-438E-BB14-B2AE328D79C8Q33711395-6C771BC1-8466-4ABF-AD4E-5528F8F79176Q33724236-F9553E22-24D5-4D62-8D81-F11F51480B26Q33938435-06B85908-393E-4CC6-B3D6-634B285967D0Q34137024-F85CEF14-C80A-4B39-AD49-74738EF115B2Q34424570-6F1C7C9A-99E0-4EF3-9135-D08F19010F3EQ34794525-49864653-D99F-4FFF-9A06-5EA8797A93D9Q35023274-1E5E0F08-451C-46A8-A847-8AE6ABFA80D1Q35199296-2E62BC31-F5E2-41F7-AE15-1B2237F11C65Q35348677-146AA266-1FE7-4BFF-841E-D227E936211FQ35561776-7CEB87A6-411D-4680-8876-14F062E99388Q36037525-3F7563F3-3073-4E5B-837A-471E7DFEC8A1Q36543422-8DF0E83F-10F4-4E85-B5C5-370C3D0ADCBBQ36571141-C33C9FF1-BB30-40E3-AFE8-243DAA92DCA0Q37007749-FB549938-910D-43A7-8398-43C52A79B16FQ37256518-081C0B81-8AA8-4519-94E6-6432C9426C3CQ37507816-430A906A-542B-4DA1-BDEF-746E8CCB1EF1Q37541716-1DA6D1CC-EF81-4123-A04C-29F5C4883125Q37621530-22B00CE0-E46C-44D1-A8CC-1060F7B91C86Q37717893-29D39B49-2E23-4C1B-911B-17A1CEAAA4A9Q38210808-2E8A9D7D-EF15-453B-BD6E-92D1C9F9087CQ38539938-DD1ABF1F-BE39-482F-9308-7B83DB726DDEQ38543280-8400178A-EDFF-4518-B19C-4413962B0940Q38574966-BCD86EFC-D60B-4127-B6F9-069A50005070Q38803022-07BF9CA5-D833-41E6-90C7-EA42DCEE2BC6Q38894155-6F551591-DAA8-4C7F-AEF3-7C007215B5CDQ39084223-82A93E46-0D81-4ADA-A3F0-C47DF06B6D9CQ39394803-860E42D5-E737-4A11-A8BB-35E7C8FF91B8Q40049410-56CC682B-D7E6-4BE8-9C16-5F9044084F05Q40073271-E4096949-AB8A-4B1E-B5D5-2BD2E81E7515Q40211579-6EA94177-9C96-4BEB-A8E3-C9666517E3D7Q40296362-9F940079-B5A7-4EE7-9404-76176CAA7CDBQ40417058-F999A47A-DDD7-4BB0-9E16-FD0890554EC5Q41931070-AFF3612F-F839-4BC4-8986-171AE2462C09Q45864205-B7C36C89-A42A-4D6A-8DE5-EC7CDACBC2BB
P2860
Effective gene therapy for haemophilic mice with pathogenic factor IX antibodies.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 16 September 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Effective gene therapy for haemophilic mice with pathogenic factor IX antibodies.
@en
Effective gene therapy for haemophilic mice with pathogenic factor IX antibodies.
@nl
type
label
Effective gene therapy for haemophilic mice with pathogenic factor IX antibodies.
@en
Effective gene therapy for haemophilic mice with pathogenic factor IX antibodies.
@nl
prefLabel
Effective gene therapy for haemophilic mice with pathogenic factor IX antibodies.
@en
Effective gene therapy for haemophilic mice with pathogenic factor IX antibodies.
@nl
P2093
P2860
P50
P921
P356
P1476
Effective gene therapy for haemophilic mice with pathogenic factor IX antibodies.
@en
P2093
David M Markusic
George Q Perrin
Paul A LoDuca
Roland W Herzog
Xiaomei Wang
P2860
P304
P356
10.1002/EMMM.201302859
P577
2013-09-16T00:00:00Z